Table I.
Clinicopathological characteristics of 20 patients with GISTs.
| Clinicopathological characteristics | Total, n (%) |
|---|---|
| Gender | |
| Male | 15 (75) |
| Female | 5 (25) |
| Age | |
| ≤58 years | 11 (55) |
| ﹥58 years | 9 (45) |
| Tumor size | |
| ≤1 cm | 7 (35) |
| 1–2 cm | 13 (65) |
| Tumor site | |
| Rectum | 8 (40) |
| Non-rectum | 12 (60) |
| Morphology | |
| Spindle | 19 (95) |
| Epithelioid | 1 (5) |
| Mixed | 0 (0) |
| Immunohistochemistry | |
| CD117 (+) | 17 (85) |
| CD34 (+) | 16 (80) |
| DOG-1 (+) | 14 (70) |
| Ki67 index | |
| ≤5% | 13 (65) |
| ﹥5% | 7 (35) |
| Mitotic index | |
| ≤5 per 50 HPFs | 14 (70) |
| >5 per 50 HPFs | 6 (30) |
| NIH risk stratificationa | |
| Very low | 14 (70) |
| Moderate | 6 (30) |
a
As the tumor site of the 20 cases was non-gastric, with diameter <2 cm, the NIH risk stratification, which only referred to mitotic index excluding tumor site and size, resulted in the same risk stratification as the statistical result of the mitotic index. GISTs, gastrointestinal stromal tumors; CD, cluster of differentiation; DOG-1, discovered on GIST-1; HPFs, high power fields; NIH, National Institutes of Health.